Jean‐pierre Boissel

Jean‐pierre Boissel's AcademicInfluence.com Rankings

Jean‐pierre Boissel

Medical

#3413

World Rank

#3881

Historical Rank

Cardiology

#361

World Rank

#372

Historical Rank

medical Degrees

Jean‐pierre Boissel

Philosophy

#9756

World Rank

#13360

Historical Rank

Logic

#6715

World Rank

#8260

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Jean‐pierre Boissel's Degrees

PhD Cardiology Université Paris Cité
Doctorate Medicine Université Paris Cité

Why Is Jean‐pierre Boissel Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jean‐pierre Boissel's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials (2000) (1189)
Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials (1999) (658)
Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. (1998) (599)
Thrombolytic therapy with streptokinase in acute ischemic stroke. (1996) (529)
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis (1993) (501)
Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis (2001) (392)
Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. (1996) (387)
Effect of Antihypertensive Drug Treatment on Cardiovascular Outcomes in Women and Men (1997) (380)
[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use]. (1999) (355)
J-Shaped Relationship between Blood Pressure and Mortality in Hypertensive Patients: New Insights from a Meta-Analysis of Individual-Patient Data (2002) (286)
A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials (2001) (271)
Low protein diets for chronic kidney disease in non diabetic adults. (2009) (263)
Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. (1997) (240)
Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials (2012) (234)
AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. (1996) (212)
Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). (1997) (212)
Evidence of clinical efficacy of homeopathy (2000) (204)
Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. (1999) (203)
Controlled low protein diets in chronic renal insufficiency: meta-analysis. (1992) (186)
Growth‐stimulating effect of catecholamines on rat aortic smooth muscle cells in culture (1983) (181)
Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. (2001) (166)
Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups (2002) (159)
Evidence of clinical efficacy of homeopathy. A meta-analysis of clinical trials. HMRAG. Homeopathic Medicines Research Advisory Group. (2000) (158)
Trials of streptokinase in severe acute ischaemic stroke (1995) (152)
Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression (2000) (144)
Comparative Safety and Tolerability of Clopidogrel and Aspirin (1999) (140)
Persistent asthma: disease control, resource utilisation and direct costs (2002) (138)
Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. (1990) (125)
Oral Beraprost Sodium, a Prostaglandin I2 Analogue, for Intermittent Claudication A Double-Blind, Randomized, Multicenter Controlled Trial (2000) (121)
Effects of bisoprolol on heart rate variability in heart failure. (1996) (119)
A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents. (2006) (119)
Surrogate endpoints: A basis for a rational approach (2006) (118)
Considerations for the meta-analysis of randomized clinical trials. Summary of a panel discussion. (1989) (117)
A systematic review of the accuracy of ultrasound in the diagnosis of deep venous thrombosis in asymptomatic patients (2004) (113)
EasyMA: a program for the meta-analysis of clinical trials. (1997) (112)
A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy. (2009) (108)
Low protein diets delay end-stage renal disease in non-diabetic adults with chronic renal failure. (2000) (102)
Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. (1998) (99)
Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project--Free Radicals. (2000) (96)
Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. (2000) (96)
Chronic Lung Allograft Dysfunction: A Systematic Review of Mechanisms (2016) (82)
Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group. (1995) (77)
Streptokinase in acute ischemic stroke: an individual patient data meta-analysis : The Thrombolysis in Acute Stroke Pooling Project. (2000) (76)
INDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary results. (1995) (74)
Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. (1981) (69)
An Effect Model for the Assessment of Drug Benefit: Example of Antiarrhythmic Drugs in Postmyocardial Infarction Patients (1993) (60)
Is It Possible to Reduce the Risk of Cardiovascular Events in Subjects Suffering from Intermittent Claudication of the Lower Limbs? (1989) (57)
Clinical Trial Simulation Using Therapeutic Effect Modeling: Application to Ivabradine Efficacy in Patients with Angina Pectoris (2002) (57)
A mathematical model of ion movements in grey matter during a stroke. (2006) (52)
Impact of randomized clinical trials on medical practices. (1989) (52)
Comparison of a rehabilitation programme, a counselling programme and usual care after an acute myocardial infarction: results of a long-term randomized trial. P.RE.COR. Group. (1991) (52)
Identification of risk factors in hypertensive patients: contribution of randomized controlled trials through an individual patient database. (1999) (51)
Quality of life assessment in therapeutic trials: rationale for and presentation of a more appropriate instrument (1992) (49)
Using Pharmacokinetic-Pharmacodynamic Relationships to Predict the Effect of Poor Compliance (2002) (48)
Airway microbiota signals anabolic and catabolic remodeling in the transplanted lung (2017) (47)
Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. (1995) (45)
Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it? (2000) (45)
A dose-effect study of beraprost sodium in intermittent claudication. (1996) (44)
Terbinafine in fungal infections of the nails: a meta‐analysis of randomized clinical trials (2002) (44)
Smoking cessation with behaviour therapy of acupuncture--a controlled study. (1983) (44)
Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. The INDANA Steering Committee. (2000) (43)
Population Pharmacokinetics of Recombinant Factor VIIa in Volunteers Anticoagulated with Acenocoumarol (1998) (43)
Why don't cancer patients enter clinical trials? A review. (2006) (41)
A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice (1995) (39)
Time course of long-term placebo therapy effects in angina pectoris. (1986) (38)
Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation (2004) (36)
Assessing treatment-time interaction in clinical trials with time to event data: a meta-analysis of hypertension trials. (1998) (36)
A global phenomenological model of ischemic stroke with stress on spreading depressions. (2008) (33)
Low protein diets delay end-stage renal disease in non diabetic adults with chronic renal failure. (2000) (32)
Treatment of High Blood Pressure and Gain in Event-Free Life Expectancy (2005) (31)
Role of astrocytes in grey matter during stroke: A modelling approach (2007) (30)
Exploration of beneficial and deleterious effects of inflammation in stroke: dynamics of inflammation cells (2009) (30)
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility (2021) (30)
Epidemiology of Viral Infections and Evaluation of the Potential Benefit of OM-85 BV on the Virologie Status of Children Attending Day-Care Centers (1994) (29)
Critical reading of the meta-analysis of clinical trials. (1995) (29)
Comparison of bioprosthesis and mechanical valves, a meta-analysis of randomised clinical trials. (2000) (29)
Pharmacotherapy for hypertension in women of different races. (2000) (29)
Individualizing aspirin therapy for prevention of cardiovascular events. (1998) (28)
Independent clinical research in Europe (2004) (28)
Controlled study of three ointments for the local management of 2nd and 3rd degree burns (1992) (27)
Efficacy of treating hypertension in women (1999) (27)
Importance of quantitative analysis of ventricular arrhythmias for predicting the prognosis in low-risk postmyocardial infarction patients. European Infarction Study Group. (1990) (27)
Bridging Systems Medicine and Patient Needs (2015) (27)
Comparison between a bid and a tid regimen: improved compliance with no improved antihypertensive effect (1996) (27)
Revisiting the effect compartment through timing errors in drug administration. (1998) (27)
Level of Control and Hospital Contacts in Persistent Asthma (2001) (27)
Mathematical Modelling of an Ischemic Stroke: An Integrative Approach (2004) (27)
QxDB: a generic database to support mathematical modelling in biology (2006) (26)
Meta-analysis and multiple publication of clinical trial reports (1992) (26)
A modelling approach to explore some hypotheses of the failure of neuroprotective trials in ischemic stroke patients. (2008) (25)
Reliability of phlebography in the assessment of venous thrombosis in a clinical trial. (1990) (25)
Myocardial Protection During Coronary Artery Bypass Graft Surgery: A Randomized, Double-Blind, Placebo-Controlled Study with Trimetazidine (1996) (25)
Modelling methodology in physiopathology. (2008) (25)
Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments (2005) (24)
New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear. (2008) (23)
The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests. (2005) (23)
Daycare attendance and risk of first infectious disease (2005) (21)
The Global Risk Approach Should Be Better Applied in French Hypertensive Patients: A Comparison between Simulation and Observation Studies (2011) (21)
Coronary Reperfusion Rates in Acute Myocardial Infarction Patients After Thrombolytic Treatment with Anistreplase: Correlation with the Delay from Onset of Symptoms to Treatment A Review of 424 Case Records of Patients Admitted to Coronary Reperfusion Studies with Anistreplase (1992) (21)
Physiologically Based Model of Acute Ischemic Stroke (2002) (21)
SCORE should be preferred to Framingham to predict cardiovascular death in French population (2009) (21)
Treatment of membranous nephropathy: a meta-analysis. (1994) (21)
Evaluation of two evidence‐based knowledge transfer interventions for physicians. A cluster randomized controlled factorial design trial: the CardioDAS Study (2007) (21)
Rationale for carbon ion therapy in high-grade glioma based on a review and a meta-analysis of neutron beam trials. (2010) (20)
[Homeopathic specialties as substitutes for benzodiazepines: double-blind vs. placebo study]. (2001) (20)
Prediction of chronic lung allograft dysfunction: a systems medicine challenge (2014) (20)
A numerical study of the blocking of migraine by Rolando sulcus. (2008) (20)
Getting Evidence to Prescribers and Patients or How to Make EBM a Reality (2003) (19)
Systematic reviews and their roles in promoting evidence-based medicine in renal disease. (1996) (19)
Which coding system for therapeutic information in evidence-based medicine (2002) (19)
Education program for general practitioners on breast and cervical cancer screening: a randomized trial. PRE.SA.GF Collaborative Group. (1995) (19)
Subjective Quality of Life Assessment in Therapeutic Trials: Presentation of a New Instrument in France (SQLP: Subjective Quality of Life Profile) and First Results (1994) (19)
A Simple Tool to Evoke Physicians' Real Training Needs (2002) (19)
Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? (2003) (18)
Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial. (2000) (18)
An in silico target identification using Boolean network attractors: Avoiding pathological phenotypes. (2014) (17)
Clockwise hysteresis or proteresis (1989) (17)
Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects. (1996) (17)
[Quality of life assessment in therapeutic trials. Conceptual aspects and presentation of a questionnaire]. (1989) (17)
Response to “inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 — The perspective of NIH clinical trialists” (1995) (17)
Prescription intentions in relation to therapeutic information: a study of 117 French general practitioners. (1991) (16)
Sick population — treated population: the need for a better definition (2004) (16)
Drug prescription in young children: results of a survey in France (2004) (16)
Optimal duration of anticoagulant therapy after an episode of venous thromboembolism (2000) (16)
Planning of clinical trials (2004) (15)
Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods. (2003) (15)
Revisiting the relationship between baseline risk and risk under treatment (2009) (15)
[Prevention of influenza A. Effectiveness and tolerance of rimantadine hydrochloride]. (1990) (14)
A mathematical model for the determination of the optimum value of the treatment threshold for a continuous risk factor (2004) (14)
Verifying and Validating Quantitative Systems Pharmacology and In Silico Models in Drug Development: Current Needs, Gaps, and Challenges (2020) (14)
[The questionnaire "Profile of the subjective quality of life". First data of validation]. (1991) (14)
Towards personalized medicine: exploring the consequences of the effect model-based approach. (2011) (14)
Meta-analysis of clinical trials: Summary of an international conference (2004) (14)
How to anticipate the assessment of the public health benefit of new medicines? (2007) (14)
Soluble Fas ligand and atherosclerosis in hypertensive patients. (2002) (13)
Use of Sensitivity Functions to Characterise and Compare the Forgiveness of Drugs (2002) (13)
I General Session (2021) (13)
Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects (1996) (13)
Meta-analysis of results from clinical trials on prevention of coronary heart disease by lipid-lowering interventions (1993) (12)
[Group meetings for patient recruitment in clinical trial in pediatrics]. (1991) (12)
Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. (1985) (12)
Use of sales statistics for evaluating prescription rationale (1983) (11)
Introduction à la méthodologie métaanalytique (1995) (11)
Registry of multicenter clinical trials. Eleventh report--1989. (1991) (11)
CONTROLLED CLINICAL TRIAL OF BEPRIDIL, PROPRANOLOL AND PLACEBO IN THE TREATMENT OF EXERCISE INDUCED ANGINA PECTORIS (1989) (11)
Quality of health information about depression on internet. Level of evidence should be gold standard. (2001) (11)
Effect Model Law: An Approach for the Implementation of Personalized Medicine (2013) (10)
[Prognostic importance of ambulatory arterial pressure monitoring in France. Initial results of the OCTAVE II study. OCTAVE II Research Group]. (1999) (10)
Experience collecting interim data on mortality: an example from the RALES study (2001) (10)
Level of Evidence as a Future Gold Standard for the Content Quality of Health Resources on the Internet (2003) (9)
Amiodarone Interaction With (cid:98) -Blockers Analysis of the Merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) Databases amiodarone in patients after myocardial infarction with sim-Received (1999) (9)
Level of evidence and therapeutic evaluation: need for more thoughts (2004) (9)
Literature search parameters marginally improved the pooled estimate accuracy for ultrasound in detecting deep venous thrombosis. (2006) (9)
Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems (2003) (9)
The meta-analysis of diagnostic test studies (1998) (9)
Revisiting the level of evidence in randomized controlled clinical trials: A simulation approach. (2009) (9)
In Silico Study of the Influence of Intensity and Duration of Blood Flow Reduction on Cell Death Through Necrosis or Apoptosis During Acute Ischemic Stroke (2010) (9)
Compliance-Guided Therapy (2006) (9)
OM-85 BV: primary versus secondary prevention. (1994) (8)
Uncorrected pre-ejection period: A simple non-invasive measurement for pharmacodynamic screening of inotropic activity (2004) (8)
Maintenance chemotherapy for small cell lung cancer. (1998) (8)
[Controlled clinical trial and homeopathic treatment of ORL and recurrent respiratory tract infections in children: preliminary survey of homeopathic physicians]. (1995) (8)
[Quality of life of patients during treatment of type I diabetes. Importance of a questionnaire focused on the subjective quality of life]. (1994) (8)
Sub-grouping of post myocardial infarction patients according to their one-year death risk. (1987) (7)
Comparative Phagocytosis in Culture of Aortic Smooth Muscle Cells and Fibroblasts from Rat 1 (1982) (7)
Trial summary software (2000) (7)
Influence of confounding factors on designs for dose-effect relationship estimates. (1995) (7)
Registry of Multicenter Clinical Trials: Twelfth and Thirteenth Report – 1990–1991 (1992) (7)
A phenomenological model of the growth of the necrotic area in ischemic stroke (2010) (6)
Subcommittee on Clinical Trials: Registry of Multicenter Clinical Trials (1991) (6)
The calculation of a confidence interval on the absolute estimated benefit for an individual patient. (1998) (6)
First Congress of the European Association for Clinical Pharmacology and Therapeutics. (1996) (5)
Are pre-ejection period changes specific for inotropic effects? (2004) (5)
Dose-ranging trials: guidelines for data collection and standardized descriptions. (1995) (5)
Therapeutic objectives. (1999) (5)
How should therapeutic information be transferred to users? (2003) (5)
Enhancing Boolean networks with fuzzy operators and edge tuning (2014) (5)
[Integratable message: central problem of communication for therapeutic information]. (1996) (5)
Comparison of an effect-model-law-based method versus traditional clinical practice guidelines for optimal treatment decision-making: application to statin treatment in the French population (2014) (4)
Systolic time intervals in evaluation of the negative inotropic effect after single oral doses of mexiletine and disopyramide (2004) (4)
Controlled clinical trials: today's challenges for statisticians and designers. (1981) (4)
Identification of responders to a therapy: An example of validation of a predictive model (1999) (4)
[Calcium channel antagonists and myocardial ischemia or ischemia/reperfusion]. (1993) (4)
Modeling and Medical Product R&D (2009) (4)
[The problem of therapeutic efficacy indices. 2. Description of the indices]. (1999) (4)
Risk reduction for stroke and coronary events (2002) (4)
Implication of evidence‐based medicine in prescription guidelines taught to french medical students: Current status in the cardiovascular field E‐mail: pn@upcl.univ-lyon1.fr (1999) (4)
From Clinical Trial Efficacy to Real-Life Effectiveness: Why Conventional Metrics do not Work (2019) (4)
Some thoughts on two-tailed tests (and two-sided designs) (1988) (4)
A controlled study of Dextran 40: effect on cerebral blood flow and metabolic rates in acute head trauma (2004) (4)
[Anticoagulant treatment of venous thromboembolic disease: optimal duration of antivitamin K therapy. Review of the literature]. (1994) (4)
How to measure non‐consistency of medical practices with available evidence in therapeutics: a methodological framework (2005) (4)
[Example of a phase IV trial involving several physicians and aiming at answering a scientific question: EOL]. (1996) (4)
Problems with intervention trials in hypertension. (1987) (4)
[Example of a method for evaluating the efficacy of a prescribers' information system]. (1984) (4)
Standards for reporting clinical trials. (1992) (4)
[Hierarchies according to the level of evidence of source data, before their integration in the synthesis, in the matter of therapeutic efficacy]. (1996) (4)
The iceberg phenomenon and publication bias: the editors' fault? (1993) (3)
HYPERTENSION OPTIMAL TREATMENT (HOT) TRIAL. AUTHORS' REPLY (1998) (3)
The SysCLAD- Systems Prediction of Chronic Lung Allograft Dysfunction Study: Aims, Strategy and First Data (2013) (3)
[The Cochrane Collaboration: the need for international collaboration]. (1996) (3)
International Committee Communications ICTH-Subcommittee on Clinical Trials Registry of Multicenter Clinical Trials Ninth Report-1987 (1988) (3)
[Clinical evaluation: from intermediate to surrogate criteria]. (1997) (3)
Heterogeneity in meta-analysis: Potential strategy of identification, analysis and practical interpretation (1991) (3)
[Identification and prediction of responders to a therapy. A model and its preliminary application to hypertension]. (1998) (3)
Antiarrhythmic Effects and Tolerability of Mexiletine in Patients with Suspected Acute Myocardial Infarction (1990) (3)
A43 Long-term survival follow-up in international clinical trials (1993) (3)
A logic-based modeling derived from boolean networks: adding fuzzy logic and edge tuning (2014) (3)
How to deal with multiple treatment or dose groups in randomized clinical trials? Another approach (2007) (3)
[Presentation of OCTAVE II. A current epidemiologic study in France of the added prognostic value of ambulatory blood pressure monitoring]. (1996) (3)
What target for guidelines: uniformed or tailored? (1998) (3)
Drugs Effect on Platelet Survival Time: Comparison of Two Pyrimido-Pyrimidine Derivatives in Patients with Aortic or Mitral Replacement (1984) (3)
[Monitoring of clinical trials and interim analysis. 1. Monitoring committee]. (1992) (3)
High Risk versus Proportional Benefit: Modelling Equitable Strategies in Cardiovascular Prevention (2015) (3)
Les claudications intermittentes (2005) (3)
[Monitoring of clinical trials and interim analysis. 2. Statistic methods]. (1992) (3)
[Consequences of discrepancies between current data of the science and medical practice]. (1996) (2)
Europe: Computerised information for prescribers (1991) (2)
[The ISIS-2 study (International Study of Infarction Survival)]. (1988) (2)
[Effect models and meta-analysis]. (1997) (2)
Inositol monophosphate esterase inhibition by lithium in normal human studies using neuroendocrine tests part I. PRL and TSH responses to TRH (1990) (2)
Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions (2022) (2)
Doctors' perception of pertinent information (1992) (2)
[Note on the necessary definition of therapeutic objectives for optimal prescription]. (1996) (2)
New tools to measure discrepancy between prescribing practices and guideline recommendations. (2007) (2)
Impact of randomized controlled trials on the progress of therapy in cardiovascular diseases. (1984) (2)
Registry of multicenter clinical trials: 14th and 15th report 1992-1993. (1996) (2)
International collaborative group on clinical trial registries (CTRs) working party on CTRs: consensus recommendations (1993) (2)
Solving the Evidence Interpretability Crisis in Health Technology Assessment: A Role for Mechanistic Models? (2022) (2)
The Eurevie Study: contrasting effect of piretanide and thiazides in mild to moderate hypertension. (1997) (2)
Determination of debrisoquine oxidation phenotype in healthy volunteers during phase I trials. (1996) (2)
E.P.S.I.M., the French oral anticoagulant--aspirin trial in post-myocardial infarction patients: design, organization and quality control procedures. (1981) (2)
Serotonergic antidepressants and obsessive-compulsive disorder. (1991) (2)
[Antihypertensive therapy and improved life expectancy without cerebrovascular accident or coronary artery disease]. (2001) (2)
Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample (2021) (2)
[Simulated cases and Minitel: a tool for the studying prescriptions]. (1992) (2)
[Intermediary and substitution criteria in the development of anti-arrhythmia agents]. (1991) (1)
ICTH(International Committee on Haemostasis and Thrombosis)--Sub committee on Clinical Trials. Registry of Multicenter Clinical Trials. Seventh Report--1985. (1986) (1)
CAPPP trial (1999) (1)
Is thrombolytic therapy beneficial to acute stroke patients? (1996) (1)
Risk reduction for stroke and coronary events. Authors' reply (2002) (1)
Dose-effect relationship estimation for thrombolytic therapy in acute myocardial infarction. (1987) (1)
Comparative transcriptomic analysis between an artificially induced SIRS in healthy individuals and spontaneous sepsis. (2015) (1)
P127 Inter-reviewer variation the validata experience (1997) (1)
[Quantitative histological study of human femoral cartilage changes in the human femoral head in relation to the pressure areas]. (1973) (1)
[Note on the epistemology of clinical pharmacology: comparison with the approach of Karl Popper]. (1999) (1)
[Pharmacology of estrogens and progestogens and cardiovascular risk]. (1999) (1)
[Remission of left ventricular hypertrophy with ramipril independently of blood pressure changes: the HYCAR study (cardiac hypertrophy and ramipril)]. (1995) (1)
1031–34 Differential Effect of Bisoprolol on Heart Rate Variability According to Heart Rate in Patients with Heart Failure (1995) (1)
Therapeutic target discovery using Boolean network attractors : avoiding pathological phenotypes (2015) (1)
[Pulmonary radiographic lesions in 330 cases of rheumatoid arthritis as compared with 330 controls]. (1972) (1)
Effects of dydrogesterone on hydroelectrolytic metabolism: a randomized double-blind study. (1990) (1)
SYSTEMATIC REVIEW OF THE ACCURACY OF ULTRASOUND IN THE DIAGNOSIS OF ASYMPTOMATIC DEEP VENOUS THROMBOSIS: PRELIMINARY RESULTS (2008) (1)
Comparison of low-dose and standard-dose oral anticoagulant therapy in patients with a mechanical prosthesis. The AREVA multicenter trial (1996) (1)
Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers (2004) (1)
Hypertension Optimal Treatment (HOT) trial (1998) (1)
Prediction of cardiovascular risk. Hypothesis of program is flawed. (1999) (1)
Enhancing Boolean networks with continuous logical operators and edge tuning (2014) (1)
[Biological markers: utilization in drug development and approval]. (2001) (1)
[PHOLY: a pilot study of drug utilization in civil hospitals in Lyon. Results]. (1998) (1)
[Methodological issues relevant to clinical research in rare diseases]. (2003) (1)
[The problem of therapeutic efficacy indices. 1. Elements of the problem]. (1999) (1)
Better defining target populations for drugs with a view to reimbursement. (2014) (1)
Clinical trial registries. (1993) (1)
[Treatment of extra-membranous glomerulonephritis with immunosuppressive agents or difficulties of meta-analysis in nephrology]. (1994) (1)
Can change in coronary lumen volume be used as a more sensitive end-point in clinical trials of prevention of restenosis after coronary angioplasty? The PRESANCE study (1994) (1)
Dietary protein and blood pressure intervention failed to slow renal disease progression. (1994) (1)
50A Critical events management (1995) (1)
THE “STAR” STUDIES: WHICH ANTIHYPERTENSIVE STRATEGY TO CHOOSE IN PATIENTS WITH UNCONTROLLED MILD-TO-MODERATE HYPERTENSION? (2000) (0)
Brief CommunicationsWhat target for guidelines: uniformed or tailored? (1998) (0)
Evaluation: impact of randomized controlled trials on medical practices (1988) (0)
Pharmacogenetic and Pharmacogenomic Studies (2003) (0)
Level of evidence to assess health content quality on the Internet (2001) (0)
75P Decreasing mortality rate with later enrollment time in CIBIS (1994) (0)
Low dose oral anticoagulation and cardiac valvular replacement: Application of the eligibility oriented randomization scheme (1992) (0)
[Not Available]. (2007) (0)
[OP.1D.08] SYNERGETIC PREVENTION OF SUDDEN DEATH BY ACEI, STATIN AND GLIFLOZIN IN TYPE 2 DIABETES: A SIMULATION STUDY (2016) (0)
Quality criteria of a meta-analysis of clinical trials (1997) (0)
[Advantages of meta-analysis of clinical trials]. (1994) (0)
P77 Impact of trials with null number of events in meta-analysis (1997) (0)
[New approaches in pharmacology: numerical modelling and simulation]. (2005) (0)
36P Critical reading of a meta-analysis of clinical trials (1994) (0)
EUDIPHARM inaugural conference (2012) (0)
[Clinical trials in general practice. The telematics solution]. (1990) (0)
P19 Efficacy/compliance relationship in a large scale trial on hypertensive patients (1993) (0)
P63 Registers of clinical trials in the regulatory affairs process (1997) (0)
A21 graphical representation of symptom and concomitant treatment relationships (1996) (0)
Empirical methods for the validation of Time-To-Event mathematical models taking into account uncertainty and variability: Application to EGFR+ Lung Adenocarcinoma (2023) (0)
33A Assessment of the variation of treatment effect over time: An example in hypertension treatment (1994) (0)
Oral paper abstracts (2022) (0)
89 An automatic coding system (1997) (0)
Estimation of treatment effect on an endpoint assessed with methods of heterogeneous sensitivity: Example of deep vein (1998) (0)
MARKERS OF BLOOD PRESSURE RESPONSE TO A FIXED DOSE OF DIURETICS OR BETABLOCKER: P1.357 (2004) (0)
[Outline of the problem of indices of therapeutic efficacy. 4. Expression of efficacy when the underlying illness is incurable. Study Group for the Indices of Efficacy]. (1999) (0)
[Identification, during development, of a methodology targeted at determining the positioning of new drugs for therapeutic strategies: examples of rheumatoid arthritis and cardiac insufficiency]. (2002) (0)
Literature abstracts (2004) (0)
[The Hypertension Cochrane Review Group. Presentation and user's guide]. (1997) (0)
What can consumers expect from pharmaceutical research (1999) (0)
The Hypertension Cochran Review Group: Presentation and usersʼ guide (1997) (0)
[Methodological critiques of protocols of clinical studies of anti-arrhythmia agents]. (1981) (0)
population application to statin treatment in the French traditional clinical practice guidelines for optimal treatment Comparison of an effect-model-law-based method versus (2014) (0)
[Meta-analysis of clinical trials: uses and pitfalls]. (2007) (0)
Quality-of-life assessment in treatment of hypertension. (1994) (0)
Potential bias in remote data entry (1998) (0)
[Comparative double-blind trial of 16091 RP and indomethacin in chronic polyarthritis]. (1969) (0)
A55 Randomization in the APOLO study: A necessary compromise between the study design and practical constraints (1993) (0)
[Seric gamma and alpha 2 globulins and prognosis of chronic lymphoid leukemia. 266 cases]. (1972) (0)
[Defining the patient population to be studied in the evaluation of treatment in myocardial ischemia]. (1987) (0)
IS BLOOD PRESSURE REALLY AN APPROPRIATE SURROGATE MARKER?: P2.370 (2004) (0)
[Meta-analysis of therapeutic trials of primary prevention in ischemic cardiopathies by hypocholesteremic treatment]. (1992) (0)
Pseudo-trials: A method to explore the effect model (1998) (0)
THE “STAR” STUDY: ANTIHYPERTENSIVE STRATEGY IN PATIENTS WITH UNCONTROLLED MILD-TO-MODERATE HYPERTENSION (2000) (0)
Comparison of Three Methods Evaluating Platelet Survival Time in Patients with Prosthetic Heart Valve (1984) (0)
08A Telematic management of center monitoring in a phase IV study (1994) (0)
41A Enhancing follow-up rate and data quality in a multicenter clinical trial: The presance study (1994) (0)
41P A mathematical model for the determination of the optimum treatment threshold in the prevention of cardiac lipid risk (1994) (0)
La Collaboration Cochrane (2005) (0)
[Therapeutic information: how to transmit current scientific data. Group VALIDATA]. (1994) (0)
Variation of treatment effect over time: A meta-analysis of hypertension trials (2004) (0)
Standardization description of dose-ranging trial protocol (1992) (0)
[OP.3B.01] VALIDATION OF FRAMINGHAM AND SCORE IN 30560 PATIENTS WITH HYPERTENSION (2017) (0)
Recruitment of infants for randomized clinical trial (1990) (0)
A67 Double versus quadruple data entry (1996) (0)
A74 A method to maintain blinding in a randomized trial requiring adjustment of doses for only one treatment arm (1996) (0)
Is the isotropy hypothesis true in hypertension findings from the Indana project (1998) (0)
Full Title: Empirical methods for the validation of Time-To-Event mathematical models taking into account uncertainty and variability: Application to EGFR+ Lung Adenocarcinoma. Short Title: Methods for the validation of mathematical models, application to lung cancer. Authors (0)
707-3 CIBIS Left Ventricular Function Sub-study: Analysis of Predictive Factors of Initial Improvement and Prognostic Value (1995) (0)
[Reflexions before the introduction of a drug prescription survey at hospitals]. (1996) (0)
Invited discussant (1979) (0)
Respiratory Immune Defense in Children: Current Knowledge and Possible Therapeutic Interventions: Satellite Symposium of the 1st International Congress on Pediatric Pulmonology - CIPP 94, Nice, June 1994: Proceedings (1994) (0)
A31 Ethical cost when the therapy target population and the dissemination population do not coincide (1996) (0)
[Critical analysis of individual data in meta-analysis. Apropos of an experience in the domain of drug treatment in arterial hypertension]. (1997) (0)
Thanks to our reviewers in 2014 (2015) (0)
[From clinical trial to prescription]. (2000) (0)
[How should one anticipate the assessment of the public health benefit of new medicines?]. (2007) (0)
[PHOLY: A pilot study of drug utilization in civil hospices in Lyon - methodology and difficulties]. (1998) (0)
Use of mortality of all screened patients to check the relevance of study population as regards to the target population in intervention studies (1986) (0)
[Introduction to meta-analytic methodology]. (1995) (0)
In silico exploration of atopic dermatitis phenotypes for clinical trial design optimization (2023) (0)
[Effect of low molecular weight dextran on cerebral blood flow, transport and oxygen consumption during the acute phase of traumatic coma]. (1987) (0)
[The Cochrane Collaboration, support of therapeutic information]. (1997) (0)
Primary prevention of stroke in hypertension is better when the renin-angiotensin and sympathetic systems are activated by the antihypertensive drugs (2001) (0)
Clinical Trials Report: Cardiovascular & Renal: Ongoing clinical trials in acute coronary syndrome (1996) (0)
Contents, Vol. 61, Supplement 1, 1994 (1994) (0)
Review: Glycoprotein IIb/IIIa-receptor antagonists reduce combined death or MI in patients with ischemic heart disease (1999) (0)
[Statistical survey by computer on the surgical treatment of disk sciatic neuralgia]. (1970) (0)
Inositol monophosphate esterase inhibition by lithium in normal human studies using neuroendocrine tests part II. HGH, PRL and TSH responses to clonidine (1990) (0)
26A Why must we perform meta-analyses on individual patient data? The indana project: An example of hypertension (1994) (0)
Using numerical modeling and simulation to assess the ethical 1 burden in clinical trials and how it relates to the proportion of 2 responders in a trial sample 3 SHORT TITLE 4 Ethical loss in randomized clinical trials 5 6 (2021) (0)
A mathematical approach to model stroke pathophysiology (2009) (0)
SYSTOLIC AND DIASTOLIC BLOOD PRESSURE LOWERING AS DETERMINANTS OF CARDIOVASCULAR OUTCOME ON ANTIHYPERTENSIVE DRUG TREATMENT: OP 047 (2004) (0)
Subject Index, Vol. 20, 1990 (1990) (0)
[Therapeutic evaluation and the level proof]. (2004) (0)
PREVENTION OF SYSTEMIC THROMBO-EMBOLISM IN PATIENTS WITH ATHEROSCLEROTIC INTERMITTENT CLAUDICATION (1987) (0)
Eptifibatide reduced deaths and nonfatal myocardial infarction in acute coronary syndromes (1999) (0)
P122 The thrombolysis in acute stroke-pooling project: A prospective meta-analysis on individual patient data (1997) (0)
Bioequivalence Evaluation of a Fixed Combination of Chloroquine and Proguanil in a Capsule Formulation versus a Standard Medication (2002) (0)
P-214: Duality of angiotensin receptors and opposite link between angiotensin II and stroke risk according to high or low prevalence of coronary disease (2002) (0)
Utility of the chemotherapy in advanced non small cell lung cancer (NSCLC): Results of a meta-analysis (1991) (0)
Contents Volume 14 (2004) (0)
Iran: Rebirth of a Timeless Empire (1977) (0)
Reply (2000) (0)
[Role of meta-analysis in the definition of target population in therapy]. (1997) (0)
[Technique for measuring the atheroma volume in men]. (1992) (0)
06A Influence of confounding factors on designs for dose effect studies (1994) (0)
89P Prevention of restenosis after coronary angioplasty: PRESANCE, a clinical trial with a factorial design using the change in lumen volume as the main end-point (1994) (0)
[Non-inferiority trial used in venous thromboembolic disease. A warily interpretation is necessary!]. (2007) (0)
Controlled clinical trial of bepridil, propranolol and placebo in the treatment of exercise induced angina pectoris. B.I.S. Research Group. (1989) (0)
Low protein diets in chronic renal insufficiency: Authors' reply (1992) (0)
86P Equivalence testing: “No difference” is not synonymous with “equivalent” (1994) (0)
Power, clinical and statistical significance of the search of interactions between treatment effect and patient profiles: A practical approach (1998) (0)
Meta analysis of unpublished subgroups data, logistical and statistical problems: The experience of the beta-blocker pooling project (BBPP) (1986) (0)
Systolic blood pressure independent treatment effect on the risk of stroke and coronary artery disease: An individual patient data meta-analysis of hypertension trials (2004) (0)
[Ethical and legal problems posed by therapeutic trials]. (1979) (0)
[Comparison of intravenous thrombolysis and intracoronary thrombolysis]. (1988) (0)
International Committee Communications. ICTH (International Committee on Thrombosis and Haemostasis). Subcommittee on Clinical Trials: Registry of Multicenter Clinical Trials. Eighth report 1986. (1987) (0)
[Prevention of secondary myocardial infarction]. (1981) (0)
P-437: Demonstration that isotropy is a fallacy in elevated blood pressure (2001) (0)
Reply: LETTERS TO THE EDITOR (2008) (0)
[Duration of survival in chronic lymphocytic leukemia (study of 336 cases by an acturarial method]. (1970) (0)
A18 Technical and architectural problems and solutions associated with registers of clinical trials (1996) (0)
·P-56 A model for comparing the efficacy of randomization procedures in controlled clinical trials (1990) (0)
Subjective quality of life assessment: A new instrument, the “SQLP” (1992) (0)
Low-dose amiodarone was better than sotalol or propafenone for preventing first recurrence of atrial fibrillation (2000) (0)
INTRODUCTION A LA PHARMACOECONOMIE (1998) (0)
[In favor of teaching medical and scientific expression. 3. Information and therapeutic trials. 2. Some useful criteria for judging the validity of a therapeutic trial]. (1971) (0)
La Collaboration Cochrane support de l'information thérapeutique (1997) (0)
[Presentation of results of a general review]. (1993) (0)
[Validation of an automatic quantification system in angiography. Research group studying ticlopidine in atherosclerosis of the lower leg]. (1989) (0)
[Methods of evaluation of anti-angina agents]. (1984) (0)
Are science and seeding “trials” compatible? (1992) (0)
P34 Proposed strategy for identifying the treatment target population (1996) (0)
Comparisons of treatments with different sets of eligibility criteria: Example of P.RE.COR. Trial (1985) (0)
Appropriate coding systems for indexing clinical trials (1998) (0)
[Intermittent claudications]. (2005) (0)
CAPPP trial. Captopril Prevention Project. (1999) (0)
[Factual medicine or how to realise a necessary and deep evolution in the medical practice]. (1996) (0)
Viral kinetic modeling and clinical trial simulation predicts disruption of respiratory disease trials by non-pharmaceutical COVID-19 interventions (2021) (0)
Why a clinician may be interested and involved in computational medicine? (2008) (0)
Choice of a radiological end-point in the evaluation of the effect of drugs on atherosclerotic lesions of restenosis after angioplasty (1991) (0)
Pharmacodynamic of growth hormone secretion after injection of synthetic growth hormone releasing factor to healthy volunteers (1990) (0)
[Information on drugs in France: subjective approach]. (1983) (0)
A predictive model of inclusion rates in a very large scale clinical trial with general practitioners (1992) (0)
A05 Use of a sequential method for monitoring safety in patients enrolled in the multicenter acute stroke trial (1993) (0)
Is thrombolytic therapy beneficial in acute stroke patients? (1996) (0)
In a pilot study, roxithromycin reduced 1 of 10 end points of ischemic cardiac disease (1998) (0)
Comparison of Bioprosthesis and Mechanical Valves, a Meta-Analysis of Randomised Clinical trials (2000) (0)
P-212: Stroke prevention in patients without coronary heart disease: A link with antihypertensive treatment effect on angiotensin and sympathetic systems ? (2002) (0)
Stopping the Randomized Aldactone Evaluation Study Early for Efficacy (2006) (0)
Clinical studies with somatocrinin (hGRF-44) in adult man (1985) (0)
[Teaching of scientific and medical expression. 3. Information and therapeutic trials. 1. Principles of methodology]. (1971) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jean‐pierre Boissel?

Jean‐pierre Boissel is affiliated with the following schools:

London School of Hygiene and Tropical Medicine

Jean‐pierre Boissel's Academic­Influence.com Rankings

Jean‐pierre Boissel's Degrees

Why Is Jean‐pierre Boissel Influential?

Jean‐pierre Boissel's Published Works

Published Works

What Schools Are Affiliated With Jean‐pierre Boissel?

Jean‐pierre Boissel's AcademicInfluence.com Rankings